These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1256 related articles for article (PubMed ID: 24190978)

  • 1. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
    Webb JR; Milne K; Nelson BH
    Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
    Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
    Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
    Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
    Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
    Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
    Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
    Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
    Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
    Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW
    Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD103 and Intratumoral Immune Response in Breast Cancer.
    Wang ZQ; Milne K; Derocher H; Webb JR; Nelson BH; Watson PH
    Clin Cancer Res; 2016 Dec; 22(24):6290-6297. PubMed ID: 27267849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
    Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
    J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
    Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
    Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
    Koh J; Kim S; Kim MY; Go H; Jeon YK; Chung DH
    Oncotarget; 2017 Feb; 8(8):13762-13769. PubMed ID: 28099920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
    Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
    Li J; Wang J; Chen R; Bai Y; Lu X
    Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.